Screener
Ironwood Pharmaceuticals IRWD Debt Repayments
Debt Repayments at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermLinesOfCredit.
The source filing: Ironwood Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:09 PM EST
- Fiscal year
- FY2025
- Accession
- 0001104659-26-020489
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Repayment of 2024 Convertible Notes | — | (200,000) |
| Proceeds from revolving credit facility | — | 150,000 |
| Costs associated with revolving credit facility | — | (2,246) |
| Repayments of revolving credit facility | — | (65,000) |
| Net cash provided by (used in) financing activities | 216 | (106,970) |
| Effect of exchange rate changes on cash and cash equivalents | (329) | (32) |
| Net increase (decrease) in cash and cash equivalents | 126,897 | (3,595) |
| Cash and cash equivalents, beginning of period | 88,559 | 92,154 |
Item 16. Form 10-K Summary
FAQ
- What is Ironwood Pharmaceuticals's debt repayments?
- Ironwood Pharmaceuticals (IRWD) reported debt repayments of $15M in Q4 2024.
- How has Ironwood Pharmaceuticals's debt repayments changed year-over-year?
- Ironwood Pharmaceuticals's debt repayments decreased by 40.0% year-over-year, from $25M to $15M.
- What does debt repayments mean?
- Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.
Ask your AI about Ironwood Pharmaceuticals's debt repayments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude